Bringing innovative medical technologies to market is more complex than ever. Today's commercial leaders face shifting care settings, mounting cost pressures, enterprise-level risk considerations, and intensifying market competition. So what separates the companies that quickly gain market traction from those that stall?
In this exclusive conversation, Paul LaViolette, CEO & Co-Chairman of Pulse Biosciences and former COO of Boston Scientific, joins Amy Siegel, Co-Founder & CEO of S2N Health, to break down the strategies that consistently differentiate the companies that achieve market leadership.
In this on-demand webinar, you'll learn:
- How top MedTech innovators systematically de-risk commercialization and create a repeatable path to market leadership
- How to build and manage trusted KOL networks that drive earlier traction and stronger clinical advocacy
- Key differences in how emerging innovators vs. strategics approach commercialization — and how each balances innovation with enterprise risk
- Practical frameworks MedTech teams can use to accelerate growth while reducing uncertainty
- The real-world lessons from decades at the frontlines of MedTech innovation — including what’s working in spaces like pulsed field ablation (PFA)
Whether you’re advancing a breakthrough technology, managing a complex and growing portfolio, or simply looking for sharper strategic guidance, this conversation offers actionable insights you can use immediately.
To view the full conversation, complete the form below.